Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012

Radiotherapy and Oncology

Volumn 112, Issue 1, 2014, Pages 140-144

  Barton, Michael B ^a,b,c   Jacob, Susannah ^a,b,c   Shafiq, Jesmin ^a,b,c   Wong, Karen ^a,b,c   Thompson, Stephen R ^c,d   Hanna, Timothy P ^a,b,c   Delaney, Geoff P ^a,b,c  

^a INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^b CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Evidence based practice; Radiotherapy; Standards; Utilisation

Indexed keywords

ANTINEOPLASTIC AGENT;

AUSTRALIA; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE NEED; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; REVIEW; SENSITIVITY ANALYSIS; TREATMENT INDICATION; EVIDENCE BASED MEDICINE; MONTE CARLO METHOD; NEOPLASMS;

AUSTRALIA; EVIDENCE-BASED MEDICINE; HUMANS; MONTE CARLO METHOD; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84908212802     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.03.024     Document Type: Article

References (37)

1. Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005;75:355-65.
2. Delaney G, Jacob S, Featherstone C, Barton MB. The role of radiotherapy in cancer treatment. Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129-37.
3. Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys 2002;53:1240-53.
4. Tyldesley S, Boyd C, Shulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973-85.
5. Kerba M, Miao Q, Zhang-Salomons J, Mackillop WJ. Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol (R Coll Radiol) 2007;19:481-9.
6. Kerba M, Miao Q, Zhang-Salomons J, Mackillop WJ. Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol 2010;22:801-9.
7. Lowrance WT, Elkin EB, Yee DS, Feifer A, et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int 2012;109:1309-14.
8. Jairam V, Roberts KB, Yu JB. Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys 2013;85:151-5.
9. Delaney G, Barton B, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast cancer: a review of the evidence. Cancer 2003;98:1977-86.
10. Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 2003;4:120-8.
11. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal cancer: a review of the evidence. Cancer 2004;101:657-70.
12. Delaney G, Jacob S, Barton M. Estimating the optimal external beam radiotherapy utilization rate for genitourinary malignancies. Cancer 2005;103:462-73.
13. Delaney G, Jacob S, Barton M. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer 2005;103:2216-27.
14. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. A review of the evidence. Cancer 2004;100:1293-301.
15. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic cancer: part I - malignancies of the cervix, ovary, vagina and vulva. Cancer 2004;101:671-81.
16. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic cancer: part II - carcinoma of the endometrium. Cancer 2004;101:682-92.
17. Delaney G, Jacob S, Barton M. Estimating the optimal radiotherapy utilization for cancer of the central nervous system, thyroid cancer, and cancer of unknown primary origin from evidence-based clinical guidelines. Cancer 2006;106:453-65.
18. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I - lymphoma. Cancer 2005;103:383-92.
19. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II - leukemia and myeloma. Cancer 2005;103:393-401.
20. Barton MB, Frommer M, Olver I, Cox C, et al. A cancer services framework for Victoria and future directions for the Peter MacCallum Cancer Institute. A report from a consortium led by the Collaboration for Cancer Outcomes Research and Evaluation (CCORE); 2003.
21. Scottish Executive Health Department and Radiotherapy Activity Planning Group. Radiotherapy activity planning for Scotland 2001-2015; 2005.
22. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books. AIHW; 2011. 16-8-2011. Available from: http://www.aihw.gov.au/acim-books/.
23. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancer. Version 1.2012. Available from: http://www.nccn.org/professionals/physician-gls/pdf/esophageal.pdf.
24. National Cancer Institute (NCI). Esophageal cancer treatment (PDQ); 2012. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/esophageal/HealthProfessional.
25. Malthaner RA, Wong RK, Spithoff K, et al. Preoperative or postoperative therapy for resectable esophageal cancer: guideline recommendations. Toronto: Cancer Care Ontario (CCO); 2008. Available from: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13962.
26. Members of the Gastrointestinal Cancer Disease Site Group, Wong R, Tey R. Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus. Program in evidence-based care evidence-based series no.2-12. Version 2. Toronto: Cancer Care Ontario (CCO). Available from: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13966 2011.
27. World Health Organisation (WHO) Country Office for India. Clinical guidelines for management of esophageal cancer in India; 2010.
28. Scottish Intercollegiate Guidelines Network (SIGN). Management of oesophageal and gastric cancer. Edinburgh: SIGN, Royal College of Physicians; 2006. Available from: http://www.sign.ac.uk/pdf/sign87.pdf.
29. Saskatchewan Cancer Agency. Provincial esophageal cancer and gastroesophageal junction cancer treatment guidelines; 2011.
30. Stahl M, Budach W, Meyer HJ, Cervantes A, On behalf of the ESMO Guidelines Working Group. Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v46-9.
31. Allum WH, Griffin SM, Watson A, Colin-Jones D, On behalf of the British Society of Gastroenterology. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50:v1-v23.
32. Anandadas CN, Clarke NW, Davidson SE, et al. Early prostate cancer - which treatment do men prefer and why? BJU Int 2010;107:17621768.
33. Williams MV, Summers ET, Drinkwater K, Barrett A. Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol 2007;19:273-86.
34. Erridge SC, Featherstone C, Chalmers R, Campbell J, et al. What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015? Eur J Cancer 2007;43:1802-9.
35. Eito AP, Cabezas SA, Ugalde PF, del Campo ER, et al. Characterization and adequacy of the use of radiotherapy and its trend in time. Radiother Oncol 2013;106:260-5.
36. Slotman BJ, Vos PH. Planning of radiotherapy capacity and productivity. Radiother Oncol 2013;106:266-70.
37. Barton MB, Delaney GP. A decade of investment in radiotherapy in New South Wales: why does the gap between optimal and actual persist? J Med Imaging Radiat Oncol 2011;55:433-41.